Targeting the Gut Microbiome for Prader-Willi Syndrome Treatment (BALPWS)

Fundació Sant Joan de Déu

Status

Completed

Conditions

Prader-Willi Syndrome

Treatments

Dietary Supplement: Probiotic

Dietary Supplement: Placebo

Study type

Interventional

Funder types

Other

Identifiers

NCT03548480

FSJD-BALPWS-2018

Details and patient eligibility

About

The gut microbiome has recently emerged as a major contributor to obesity, systemic inflammation, and metabolic disease. Furthermore, intestinal bacteria are crucial players in the gut-brain axis, regulating a broad range of central nervous system processes, from satiety mechanisms to anxiety and social behavior. Thus, targeting the microbiome is being actively investigated as a therapeutic strategy for a wide array of diseases, including obesity, anxiety, depression, and autism. Among all intestinal bacteria, Bifidobacterium animalis spp. lactis (BAL) has shown promise for obesity treatment in experimental animal models and human subjects, improving body composition and metabolic health, and reducing energy intake. Moreover, tryptophan metabolism, a crucial regulator of satiety mechanisms and anxiety, is a main target of BAL. Given that clinical manifestations of Prader-Willi syndrome (PWS) include hyperphagia, anxiety, altered body composition, and metabolic dysregulation, the aforementioned effects of BAL might prove highly beneficial for children with PWS. Here, the investigators will test this hypothesis by performing a randomized double-blinded placebo-controlled crossover clinical study to assess the effects of BAL supplementation on an array of clinical manifestations of PWS. Children with PWS will undergo a 3-month placebo/probiotic treatment period, a 3-month washout period, followed by a 3-month probiotic/placebo supplementation. Anthropometric, biochemical, and psychological data as well as biological samples will be obtained at the beginning of the study, and after each of the study periods, with a total of four time-points. Specifically, the investigators will determine body composition by DXA analysis; metabolic health by assessing glucose and lipid metabolic parameters as well as circulating hormonal and cytokine levels; thermoregulation by non-invasive thermal imaging; and hyperphagia and emotional and behavioral problems by applying parental-rated validated questionnaires.

Enrollment

39 patients

Sex

All

Ages

2 to 19 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Diagnosed with Prader-Willi Syndrome with genetic confirmation
On a stable diet and medication regimen for at least the last two months before enrollment

Exclusion criteria

Current enrollment in or discontinuation within the last 30 days from a clinical trial
Presence of other medical problems that would preclude study participation
Patients with a history of bariatric surgery
Unsuitable for inclusion in the study in the opinion of the investigator